NYSEHealth CareHealth Care EquipmentS&P SmallCap 600
$20.21
-5.12 (-20.21%)
Close of Nov 06, 2026 · end-of-day data
AORT 8-K filings in 2025
Every material Form 8-K Artivion filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Artivion reported third-quarter 2025 revenue of $113.4 million, up 18% from $95.8 million a year earlier, and net income of $6.5 million, or $0.13 per diluted share, compared with a net loss of $2.3 million in the prior-year quarter. The company raised the midpoints of its full-year 2025 revenue and adjusted EBITDA guidance, which points to continued growth for shareholders.
Q3 2025 revenue was $113.4 million, up 18% on a GAAP basis and 16% on a constant currency basis
Q3 2025 adjusted EBITDA rose 39% to $24.6 million from $17.7 million; net income was $6.5 million, or $0.13 per diluted share
Full-year 2025 revenue guidance is now $439 million to $445 million, up from $435 million to $443 million; adjusted EBITDA guidance is now $88 million to $91 million, up from $86 million to $91 million
The company refinanced its credit agreement, extending maturity to 2031 and gaining a new $150 million delayed draw term loan facility
Artivion entered into two real estate purchase contracts on September 26, 2025, to buy two Austin, Texas properties for a combined $20.5 million in cash. The buildings at 1300 East Anderson Lane house its On-X manufacturing operation, and the adjacent 1200 property would let the company expand its Austin footprint as capacity needs rise.
1300 East Anderson Lane purchase: $12.05 million cash; about 75,000 square feet of manufacturing, lab, warehouse and office space the company currently leases
1200 property purchase: $8.45 million cash for a building of about 87,000 square feet adjacent to the 1300 property
Feasibility periods of 45 days (1300) and 100 days (1200) allow the company to withdraw; closings expected within 30 days after each period ends
Artivion entered into a Second Amendment to its Credit and Guaranty Agreement on September 12, 2025, with Ares Capital Corporation as administrative agent. The amendment extends the maturity of its existing term loans and revolving credit facility by one year to January 18, 2031, lowers the interest rate margins on those facilities, and adds a new $150.0 million secured delayed draw term loan. For shareholders, the filing shows added borrowing capacity and a longer repayment timeline, but also a new direct financial obligation tied to the company's debt.
Maturity of existing term loans and revolving credit facility extended one year to January 18, 2031
New $150.0 million secured delayed draw term loan available to borrow on or before September 12, 2027, subject to a maximum total net leverage ratio
Proceeds may fund permitted acquisitions, other permitted investments and capital expenditures
Prepayment premium of 1.00% applies to term loan prepayments made before July 18, 2027
Artivion's board appointed Chief Financial Officer Lance A. Berry as Chief Operating Officer, effective August 11, 2025, while he keeps his CFO and Treasurer roles. Chief Medical Officer Marshall S. Stanton will retire effective March 31, 2026, and the company expects him to provide advisory and transition services for up to one year afterward. The filing discloses no financial results, and the changes are leadership and compensation matters.
Lance A. Berry appointed COO by the board on August 6, 2025, effective August 11, 2025, in addition to his CFO and Treasurer roles
Berry's compensation includes a $540,000 base salary, a bonus target of 70% of base salary, and a target equity grant of $2,250,000 starting in 2026
Marshall S. Stanton, Senior Vice President, Clinical Research and Chief Medical Officer, will retire effective March 31, 2026, with no disagreement cited
Stanton is expected to provide strategic advice and transition services for up to one year after his retirement date
Artivion reported second-quarter 2025 revenue of $113.0 million, up 15% from a year earlier, and swung to a GAAP net income of $1.3 million from a net loss of $2.1 million. The company raised the midpoint of its full-year 2025 reported revenue guidance to $435 million to $443 million and its adjusted EBITDA guidance to $86 million to $91 million, and said it retired its $99.5 million of convertible notes due July 1, 2025 through an exchange for common stock.
Q2 2025 revenue was $113.0 million versus $98.0 million in Q2 2024, up 15% on a GAAP basis and 14% in constant currency.
GAAP net income was $1.3 million, or $0.03 per diluted share, compared with a net loss of $2.1 million, or $0.05 per share, a year earlier.
Full-year 2025 reported revenue guidance rose to $435 million to $443 million from $423 million to $435 million; adjusted EBITDA guidance is now $86 million to $91 million.
Adjusted EBITDA rose 33% to $24.8 million in Q2 2025 from $18.6 million in Q2 2024.
Artivion reported first quarter 2025 revenue of $99.0 million, up 2% on a GAAP basis, but swung to a GAAP net loss of $0.5 million, or $(0.01) per share, from net income of $7.5 million a year earlier. The company raised the midpoint of its full year 2025 revenue guidance to $423 to $435 million, while its adjusted EBITDA outlook of $84 to $91 million was unchanged. The quarter was affected by the November 2024 cybersecurity incident, which reduced preservation services revenue by 23%.
Q1 2025 revenue was $99.0 million versus $97.4 million in Q1 2024, up 2% on a GAAP basis and 4% on a constant currency basis.
GAAP net loss was $(0.5) million, or $(0.01) per diluted share; non-GAAP net income was $2.5 million, or $0.06 per diluted share.
Adjusted EBITDA rose 1% to $17.5 million from $17.3 million a year earlier.
Full year 2025 revenue guidance is $423 to $435 million; adjusted EBITDA guidance remains $84 to $91 million.
Artivion reported fourth quarter 2024 revenue of $97.3 million, up 4% on a GAAP basis, and a net loss of $16.5 million, or $(0.39) per share, compared with a net loss of $4.0 million, or $(0.10) per share, a year earlier. For full year 2024, revenue rose 10% to $388.5 million and the net loss narrowed to $13.4 million. The company expects 2025 revenue of $420 million to $435 million and adjusted EBITDA of $84 million to $91 million, and said a late November 2024 cybersecurity incident negatively affected fourth quarter revenue.
Q4 2024 revenue $97.3 million, up 4% GAAP and 3% constant currency versus Q4 2023
Q4 2024 net loss $(16.5) million, or $(0.39) per diluted share, versus $(4.0) million, or $(0.10), in Q4 2023
Full year 2024 revenue $388.5 million, up 10%; adjusted EBITDA $71.3 million, up 32%
2025 outlook: revenue $420 million to $435 million; adjusted EBITDA $84 million to $91 million
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Artivion filing is on SEC EDGAR ↗. 8-K briefs of other companies →